• Recruiting

NCT04268498: Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)

Updated: Sep 25

The ADVANCE trial

Dara-KRd

KRd

VRd

ADVANCE MYELOMA TRIAL dara-krd UNIVERSITY MIAMI

NCT04268498: A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (ADVANCE)


This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the standard of care treatment, which is lenalidomide, bortezomib, and dexamethasone (VRD).


Sponsor

University of Miami


Collaborator

Amgen


Multiple locations

International Study

 

ClinicalTrials.gov Identifier: NCT04268498

Official Title: Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

First Posted: February 13, 2020

Click here for details on ClinicalTrials.gov

 

Daratumumab : National Cancer Institute

Daratumumab : MedlinePlus Drug Information


Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information

Lenalidomide: National Cancer Institute

Lenalidomide: MedlinePlus Drug Information


Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

 

Drug: Bortezomib (Velcade)

Drug: Dexamethasone (Decadron)

Drug: Lenalidomide (Revlimid)

Drug: Acetaminophen

Drug: Diphenhydramine

Drug: Montelukast

Drug: Carfilzomib (Kyprolis)

Drug: Daratumumab (Darzalex)

Biological: Autologous Stem Cell Transplant (ASCT)

 

Daratumumab - Patient Information

Carfilzomib (Kyprolis) - Patient Information

Revlimid (lenalidomide) - Patient Information

Dexamethasaone (Decadron) and other Steroids - Patient Information

Bortezomib (Velcade) - Patient Information

 

- Florida: Sylvester Comprehensive Cancer Center - University of Miami

- Florida: Moffitt Cancer Center Tampa

- Illinois: Rush University Medical Center Chicago

- New York: Roswell Park Cancer Institute Buffalo

- New York: Memorial Sloan-Kettering Cancer Center New York

- Texas: The University of Texas MD Anderson Cancer Center Houston

 

Locations

United States, Florida

United States, Illinois

United States, New York

United States, Texas

United States, Utah

Sweden

 

RELATED POSTS


NCT03710603: Phase 3 (Perseus) EMN17 - Dara-VRd Vs VRd - Daratumumab, VELCADE, Len, Dex VS VELCADE, Len, Dex in NDMM

Click here for details


NCT03652064: Phase 3 (CEPHEUS) MMY3019 - Dara-VRd Vs VRd - Bortezomib, Lenalidomide, Dex and +/- Daratumumab - NDMM

Click here for details


NCT04566328: Phase 3 (EQUATE) - EAA181 - Dara-VRd Vs Dara-Rd - Testing the Use of Combination Therapy in NDMM

Click here for details


NCT02195479: Phase 3 (ALCYONE) Dara-VMP Vs VMP - Bortezomib, Melphalan, Prednisone & Daratumumab

Click here for details


NCT02541383: Phase 3 (CASSIOPEIA) Dara-VTd Vs VTd - Bortezomib, thalidomide, dex +/-Daratumumab before & after ASCT

Click here for details


NCT02874742: Phase 2 (GRIFFIN) - Dara-VRd Vs VRd - Daratumumab, Len., Bortezomib & Dex in NDMM

Click here for details


NCT03290950: Phase 2 (Manhattan) Dara-KRd - A Study of Daratumumab in Patients With NDMM wKRd-D

Click here for details


NCT02252172: Phase 3 (MAIA) Dara-Rd Vs Rd - Dara, Lena & Dex VS Len & Dex in previously untreated Myeloma

Click here for details


NCT03729804: Phase 3 (COBRA) - KRd Vs VRd in Patients with Newly Diagnosed Multiple Myeloma

Click here for details


NCT04096066: Phase 3 KRd Vs Rd - A Trial That Compare Two Treatments TIE - NDMM

Click here for details


NCT01402284: Phase 2 - KRd - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients

Click here for details

 

NCT04483739: Phase 3 (Iskia) - Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Eligible for ASCT

Click here for details


NCT03319667: Phase 3 (IMROZ) - Isa-VRd Vs VRd - Isatuximab, Bortezomib, Lenalidomide and Dex NDMM

Click here for details


NCT04751877: Phase 3 (IFM2020-05) - Isa-VRd Vs Isa-Rd - Non-Frail NTE Myeloma Elderly Patients

Click here for details

 

NCT04923893: Phase 3 (CARTITUDE-5) VRd --> Cilta-cel Vs VRd --> Rd - NDMM- (No ASCT planned)

Click here for details


NCT05257083: Phase 3 (CARTITUDE-6) DVRd -> Ciltacabtagene Autoleucel Vs DVRd -> Transplant ASCT- NDMM

Click here for details

 

NCT01850524: Phase 3 (TOURMALINE-MM2) Ixa-Rd Vs Rd - Oral Ixazomib + Lenalidomide/Dex Vs Placebo + Len/Dex NDMM

Click here for details